(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient ...
FDA final approval confirms therapeutic equivalence to Hospira’s methotrexate injection USP at identical strengths and vial presentations, enabling market entry via the abbreviated generic pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results